Přihlásit se Zaregistrujte se zdarma

% krátkých akcií společnosti AC Immune SA

Jaká je hodnota metriky % krátkých akcií společnosti AC Immune SA?

Hodnota metriky % krátkých akcií společnosti AC Immune SA je 1.21%

Jaká je definice metriky % krátkých akcií?



% krátkých akcií (Short% of float) je počet akcií prodaných na krátko v porovnání se všemi akciemi v oběhu (float) vyjádřený v procentech.

Short percentage of float, or short interest ratio, is calculated by taking the total amount of shares shorted and dividing it by the total amount of shares available for trade. It is an indirect metric of investor sentiment. When short percentage of float is high, above 40%, it implies company investors hope shares will decline in value. The percentage is used by both fundamental and technical traders to identify trends. The short percentage of float can also be calculated for entire exchanges to determine the sentiment of the market as a whole. If it is high of around five or greater for an exchange, this can be taken as a bearish signal, and vice versa.

% krátkých akcií společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností AC Immune SA

Čemu se věnuje společnost AC Immune SA?

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor

Firmy s metrikou % krátkých akcií podobnou společnosti AC Immune SA